Yale spinout re-engineers an immunotherapy GSK, others once abandoned
Beginning in 2004, GlaxoSmithKline ran 5 different trials to see if giving patients a molecule called IL-18 could treat their cancers. An early form of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.